$FMS · Fresenius Medical Care AG
Fresenius Medical Care filed its Q3 2026 6-K, reporting revenue of €4.937B (+1% as reported, -1% constant currency) and net income attributable to shareholders of €160M, down 42% YoY. Operating income fell 19% to €384M with margins compressing to 7.8% from 9.8%. EPS declined 35% to €0.61.
- Q3 revenue €4.937B, up 1% as reported but down 1% in constant currency
- Q3 operating income fell 19% to €384M; operating margin contracted from 9.8% to 7.8%
- Q3 net income attributable to shareholders plunged 42% YoY to €160M; EPS dropped 35% to €0.61
- Income from equity method investees collapsed 61% to €18M, driven by VFMCRP pharmaceutical JV
- Other operating expense nearly doubled to €241M, including €77M in impairment losses
Stock down 3.10% to $21.91 in regular trading, reflecting the sharp earnings deterioration. The 42% net income drop and margin compression are driving the negative reaction.
The 42% net income drop and 200bp operating margin contraction signal structural earnings deterioration beyond currency headwinds, with impairment charges and JV income collapse as key drivers.
Dialysis peers face similar reimbursement pressure, but FMS's margin erosion is amplified by the VFMCRP JV income decline and rising other operating expenses, which are company-specific headwinds.
Impairment losses of €77M in Q3 (€192M YTD) signal asset quality deterioration, concentrated in Care Enablement. The VFMCRP equity-method income collapse raises questions about the pharmaceutical JV's trajectory.